invivomab anti mouse 4 1bb agonistic antibody  (Bio X Cell)

Journal: Signal Transduction and Targeted Therapy

Article Title: Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma

doi: 10.1038/s41392-024-02105-7

Figure Lengend Snippet: PU.1 modulated PD-1/PD-L1 and 4-1BB/4-1BBL-mediated FL cell interaction with cDC1. a Immune checkpoints with differential expression between the cDC1 high and low groups identified by RNA sequencing. b Correlation between PU.1 and PD-L1, as well as PU.1 and 4-1BBL expression calculated by Pearson correlation coefficient analysis. c Relative luciferase activities in PD-L1 WT or PD-L1 MUT transfected HEK-293T cells, SC1 cells, DOHH2 cells were detected. Mean with SD was presented ( n = 3). d Relative luciferase activities in 4-1BBL WT or 4-1BBL MUT transfected HEK-293T cells, SC1 cells, DOHH2 cells were detected. Mean with SD was presented ( n = 3). e Western blot of PU.1, PD-L1, and 4-1BBL expression in the SpCas9-PU.1 transfected SC1 cells and pGMLV-PU.1 transfected DOHH2 cells

Article Snippet: For PD-L1 and 4-1BB antibody treatment, each mouse received an injection of 200 μg anti-mouse 4-1BB agonistic antibody (BE0296, Bioxcell, Lebanon, USA) and anti-mouse PD-L1 antibody (BE0101, Bioxcell) via the tail vein, three times each week for 2 weeks.

Techniques: Quantitative Proteomics, RNA Sequencing, Expressing, Luciferase, Transfection, Western Blot

Journal: Signal Transduction and Targeted Therapy

Article Title: Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma

doi: 10.1038/s41392-024-02105-7

Figure Lengend Snippet: Dual targeting PD-L1 and 4-1BB counteracted PU.1-mediated cDC1 alterations in vitro . a Cell growth of the SpCas9-PU.1-transfected SC1 co-culture system, treated with or without the bi-specific PD-L1/4-1BB antibody assessed by MTT assay. Mean with SD was presented ( n = 5). b cDC1 absolute cell numbers in the SpCas9-PU.1 transfected SC1 co-culture system treated with or without bi-specific PD-L1/4-1BB antibody assessed by flow cytometry. Mean with SD was presented ( n = 3). c cDC1 maturation in the SpCas9-PU.1 transfected SC1 co-culture system treated with or without bi-specific PD-L1/4-1BB antibody assessed by flow cytometry. Mean with SD was presented ( n = 3). d cDC1 endocytic activity in the SpCas9-PU.1 transfected SC1 co-culture system treated with or without bi-specific PD-L1/4-1BB antibody assessed by flow cytometry. Mean with SD was presented ( n = 3). e LC3B expression in the SpCas9-PU.1 transfected SC1 co-culture system treated with or without bi-specific PD-L1/4-1BB antibody. Mean with SD was presented ( n = 3). f Typical autophagosomes in the SpCas9-PU.1-transfected SC1 co-culture system, with or without bi-specific PD-L1/4-1BB antibody treatment assessed by transmission electron microscope. Cells were counted from randomly selected fields ( n = 5). Mean with SD was presented

Article Snippet: For PD-L1 and 4-1BB antibody treatment, each mouse received an injection of 200 μg anti-mouse 4-1BB agonistic antibody (BE0296, Bioxcell, Lebanon, USA) and anti-mouse PD-L1 antibody (BE0101, Bioxcell) via the tail vein, three times each week for 2 weeks.

Techniques: In Vitro, Transfection, Co-Culture Assay, MTT Assay, Flow Cytometry, Activity Assay, Expressing, Transmission Assay, Microscopy

Journal: Signal Transduction and Targeted Therapy

Article Title: Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma

doi: 10.1038/s41392-024-02105-7

Figure Lengend Snippet: Combined treatment of PD-L1 and 4-1BB antibody exhibited in vivo anti-lymphoma activity on PU.1-altered murine xenograft model. a SpCas9-scramble and SpCas9-PU.1 cells were injected subcutaneously treated with or without lenalidomide, or co-treated with PD-L1 and 4-1BB antibody. Tumor size was measured. Mean with SD was presented ( n = 3). b Standardized uptake value intensity in SpCas9-scramble group and SpCas9-PU.1 group treated with or without lenalidomide, or co-treated with PD-L1 and 4-1BB antibody assessed by Micro PET-CT. c , d cDC1 maturation in SpCas9-scramble group and SpCas9-PU.1 group treated with or without lenalidomide, or co-treated with PD-L1 and 4-1BB antibody assessed by flow cytometry. Mean with SD was presented ( n = 3). e Flow cytometry analysis of cDC1 endocytic activity in SpCas9-scramble group and SpCas9-PU.1 group treated with or without lenalidomide, or co-treated with PD-L1 and 4-1BB antibody. Mean with SD was presented ( n = 3). f Typical autophagosomes in the SpCas9-scramble group and SpCas9-PU.1 group, with or without lenalidomide treatment, or co-treated with PD-L1 and 4-1BB antibody assessed by transmission electron microscopy. Cells were counted from randomly selected fields ( n = 5). Mean with SD was presented

Article Snippet: For PD-L1 and 4-1BB antibody treatment, each mouse received an injection of 200 μg anti-mouse 4-1BB agonistic antibody (BE0296, Bioxcell, Lebanon, USA) and anti-mouse PD-L1 antibody (BE0101, Bioxcell) via the tail vein, three times each week for 2 weeks.

Techniques: In Vivo, Activity Assay, Injection, Micro-PET, Flow Cytometry, Transmission Assay, Electron Microscopy